Sutro Biopharma, Inc. develops next-generation antibody-drug conjugates (ADCs) for cancer therapy. The company utilizes a cell-free platform to engineer single- and dual-payload ADCs, optimizing the antibody, linker, and payload to enhance drug exposure and minimize side effects. Sutro's pipeline focuses on addressing large oncology markets with limited treatment options, aiming to provide more effective and safer therapies for patients with cancer.
